Molecular Pharmacology (USA) Ltd
Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in v… Read more
Molecular Pharmacology (USA) Ltd (MLPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2014: 0.015x
Based on the latest financial reports, Molecular Pharmacology (USA) Ltd (MLPH) has a cash flow conversion efficiency ratio of 0.015x as of September 2014.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.28K) by net assets ($-2.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Molecular Pharmacology (USA) Ltd - Cash Flow Conversion Efficiency Trend (2006–2014)
This chart illustrates how Molecular Pharmacology (USA) Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Molecular Pharmacology (USA) Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecular Pharmacology (USA) Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nyle International Corp
OTCGREY:NYLE
|
N/A |
|
AMALGAMATED REGIONAL TRADING (ART) HOLDINGS LIMITED
XZIM:ARTD
|
N/A |
|
EUROAFRICA DIGITAL VENT.
F:9BX
|
N/A |
|
Worldwide Holdings Corp
PINK:WWDH
|
N/A |
|
Hutn Inc
PINK:HUTN
|
-3.353x |
|
Puissant Industries Inc
PINK:PSSS
|
4.065x |
|
Hop-On Inc
PINK:HPNN
|
0.000x |
|
Itonis Inc
PINK:ITNS
|
0.001x |
Annual Cash Flow Conversion Efficiency for Molecular Pharmacology (USA) Ltd (2006–2014)
The table below shows the annual cash flow conversion efficiency of Molecular Pharmacology (USA) Ltd from 2006 to 2014.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2014-06-30 | $-2.23 Million | $-105.41K | 0.047x | -53.04% |
| 2013-06-30 | $-2.05 Million | $-206.47K | 0.101x | +17.30% |
| 2012-06-30 | $-2.08 Million | $-178.24K | 0.086x | +32.55% |
| 2011-06-30 | $-1.97 Million | $-127.16K | 0.065x | -23.14% |
| 2010-06-30 | $-1.49 Million | $-125.08K | 0.084x | +44.47% |
| 2009-06-30 | $-1.29 Million | $-75.18K | 0.058x | -83.37% |
| 2007-06-30 | $-1.31 Million | $-459.24K | 0.350x | -74.12% |
| 2006-06-30 | $-288.36K | $-390.04K | 1.353x | -- |